The BTX / Botulinum Toxin Treatment Notes Template (Dental Context)

The GDC prohibits dentists from remote prescribing for non-surgical cosmetic procedures such as Botox — the assessment has to be face to face. Below is a template for UK clinicians to paste into their PMS for any compliant BTX administration.

Why this BTX / botulinum toxin treatment template wins

• Face-to-face assessment EXPLICIT — GDC Guidance on prescribing medicines prohibits remote prescribing for non-surgical cosmetic procedures.
• Indemnity confirmation documented — BTX is high-risk for indemnity disputes if not specifically covered.
• Pre-treatment photographs — good practice for any facial aesthetic or therapeutic BTX record.
• Batch / lot number — traceability if an adverse event is reported.
• Injection sites + units mapped — defends against asymmetry or over-dose claims.
• Cooling-off period documented — JCCP best practice for cosmetic procedures.

The template (paste into your PMS notes field)

Paste the BTX / botulinum toxin treatment template below into your PMS notes field. Patient demographics are left out because your PMS already holds them.

INDICATION: [Therapeutic — bruxism / TMD myofascial pain adjunct / Cosmetic — glabellar / forehead / crow's feet / "gummy smile" correction]

AGE CHECK (Botulinum Toxin and Cosmetic Fillers (Children) Act 2021, England):
- DOB: [ ]
- Patient 18 or over: [Y]
- If under 18: DO NOT administer unless acting on the directions of a registered medical practitioner — record the doctor and the direction

GDC SCOPE CHECK:
- Dentist as registered prescriber: Y
- Trained and competent in BTX: [Confirmed — qualification + practical experience documented]
- Indemnity confirmed covers BTX provision: [Y — verified with DDU/Dental Protection/MDDUS]
- Face-to-face assessment mandatory (NOT remote): Y — patient seen in person today

MEDICAL HISTORY:
- Neuromuscular disorders: [Myasthenia gravis / Lambert-Eaton / motor neurone disease — CONTRAINDICATED]
- Aminoglycosides currently or recently: [Potentiates BTX — caution]
- Pregnancy / breastfeeding: [CONTRAINDICATED]
- Anticoagulants: [Y/N — caution with bruising]
- Previous BTX reaction: [Y/N]
- Other medications: [Reviewed]
- Allergies: [Botulinum toxin allergy — CONTRAINDICATED; other allergies]
- Mental health: [Realistic expectations / motivation / body dysmorphic disorder screen]

FACIAL ASSESSMENT:
- Facial symmetry: [Documented]
- Areas of concern: [Mapped on diagram or photograph]
- Muscle palpation: [Assessed for bruxism cases]
- Skin condition: [Acne / lesions at injection sites]

PRE-TREATMENT PHOTOGRAPHS: [Front / oblique L / oblique R / lateral L / lateral R — STORED IN PATIENT RECORD]

CONSENT (Montgomery — written, indemnity-recommended for cosmetic procedures):
- Risks: ptosis (eyelid droop), brow asymmetry, "frozen" appearance, headache, bruising, infection at injection site, spread to nearby muscles, NEED FOR REPEAT (effect lasts 3-4 months), NO GUARANTEE of specific outcome, allergic reaction (rare)
- Benefits: per indication
- Alternatives: per indication — for bruxism: occlusal splint; for cosmetic: skincare, fillers, surgical alternatives
- Cooling-off period: 14 days offered between consultation and first treatment (best practice per JCCP)
- Written consent SIGNED and dated

PRESCRIPTION DETAILS:
- Product: [Brand — Botox (Allergan) / Bocouture (Merz) / Azzalure (Galderma) / specific]
- Strength: [Vial size + concentration after reconstitution]
- Batch / lot number: [RECORDED — traceability]
- Expiry date: [Recorded]
- Reconstitution: [Saline volume used]

INJECTION SITES AND UNITS (per site — document on diagram):
[Sketch or describe systematically]
- Site 1: __ units
- Site 2: __ units
- Site 3: __ units
[Continue per site]
- TOTAL UNITS: __

INJECTION TECHNIQUE:
- Needle: [Size — 30G or 31G typical]
- Patient position: [Seated upright]
- Skin preparation: [Antiseptic wipe]
- Injection depth: [Per site — IM for muscle / superficial dermal for some cosmetic]

POST-PROCEDURE OBSERVATION:
- Immediate adverse reaction: [None / specify]
- Patient stable: [Y]

POST-PROCEDURE INSTRUCTIONS (verbal + written):
- Avoid rubbing or massaging treated area 4 hours
- Avoid lying flat 4 hours (may cause migration)
- Avoid heavy exercise 24 hours
- Avoid alcohol 24 hours
- Effect onset: typically 3-7 days
- Maximum effect: 2 weeks
- Duration: 3-4 months typically — repeat treatments may be needed

POST-TREATMENT PHOTOGRAPH: Taken today (immediate post). 2-week review photograph at next visit.

REVIEW: 2 weeks
- Assess outcome vs intended effect
- Top-up if needed (additional small doses to fine-tune)
- Photograph for comparison
- Maintenance schedule discussed

Try the BTX / botulinum toxin treatment note in the live demo → No account needed.

What good looks like — a worked example

The same BTX / botulinum toxin treatment template, completed for a realistic case.

INDICATION: Therapeutic — masseteric BTX for bruxism + masseteric hypertrophy + TMD pain.

AGE CHECK: DOB 1990-02-11 on file. Patient 34, confirmed 18 or over. No doctor's direction required.

GDC SCOPE CHECK:
- Dentist as registered prescriber: Yes
- Trained and competent in BTX: Yes — certified course (CPD certificate on file) + 5 years practical experience
- Indemnity: Confirmed with Dental Protection includes BTX cover for therapeutic indications
- Face-to-face assessment: YES — patient examined in person today, second consultation since initial (cooling-off period observed)

MEDICAL HISTORY:
- Neuromuscular disorders: None
- Aminoglycosides: None
- Pregnancy / BF: N/A (not pregnant, not breastfeeding)
- Anticoagulants: None
- Previous BTX: None
- Other medications: None
- Allergies: NKDA. No previous botulinum toxin reaction (first-time treatment).
- Mental health: Realistic expectations. Motivated for therapeutic (functional, not cosmetic) outcome. No body dysmorphic features.

FACIAL ASSESSMENT:
- Facial symmetry: Slightly asymmetric — right masseter visibly larger than left (clinical hypertrophy)
- Areas: Bilateral masseters
- Muscle palpation: Right masseter tender (4/4 on previous assessment), left masseter mildly tender (2/4)
- Skin: Clear, no lesions at planned injection sites

PRE-TREATMENT PHOTOGRAPHS: Front + oblique L + oblique R taken with patient relaxed and clenching. STORED in patient record.

CONSENT (Montgomery — WRITTEN signed today):
- Risks discussed in detail: bruising (small risk at injection sites), facial asymmetry (especially if uneven dosing — discussed careful dose matching), temporary chewing weakness (will eat softer foods first 2 weeks), need for repeat treatment (every 3-4 months for ongoing benefit), spread to adjacent muscles (rare at correct injection depth), no guarantee of specific outcome (response varies between patients), allergic reaction (very rare — first-time treatment)
- Benefits: reduction in masseter bulk + reduction in clenching force + TMD pain relief (alongside continued splint therapy)
- Alternatives: continued splint alone (helped partially), specialist referral for orofacial pain management
- Cooling-off period: 14 days observed (consultation 2 weeks ago, treatment today)
- WRITTEN consent signed today

PRESCRIPTION:
- Product: Bocouture (incobotulinumtoxinA, Merz)
- Strength: 100 units per vial, reconstituted with 2.0ml 0.9% sterile saline → 50 units/ml
- Batch / lot number: [BC-2026-04-1234]
- Expiry: 2027-03

INJECTION SITES AND UNITS (mapped on photograph):
- Right masseter: 4 injection sites along belly of muscle (palpated during clenching)
  - Site 1 (upper anterior): 5 units
  - Site 2 (upper posterior): 5 units
  - Site 3 (lower anterior): 5 units
  - Site 4 (lower posterior): 5 units
  - Subtotal right: 20 units
- Left masseter: 4 sites mirror-image
  - Each site: 4 units (slightly less than right given less hypertrophy)
  - Subtotal left: 16 units
- TOTAL UNITS: 36 units

INJECTION TECHNIQUE:
- Needle: 30G ½ inch
- Position: Patient seated upright, instructed to clench during injection (helps identify muscle belly)
- Skin prep: Antiseptic wipe per site
- Depth: IM (intra-masseteric), perpendicular to skin to mid-muscle depth (~10mm)

POST-PROCEDURE OBSERVATION:
- Immediate: No adverse reaction. No syncope.
- Patient stable.

POST-PROCEDURE INSTRUCTIONS (verbal + written):
- No rubbing of injection sites 4 hours
- Avoid lying flat 4 hours
- No heavy exercise 24 hours
- Avoid alcohol 24 hours
- Effect onset: 5-7 days
- Maximum effect: 2 weeks
- Duration: 3-4 months — repeat treatment every 3-4 months for sustained therapeutic effect

POST-TREATMENT PHOTOGRAPH: Taken immediately post-injection (baseline for comparison at 2-week review).

REVIEW: 2 weeks
- Assess masseter reduction and clenching force change
- Touch-up doses if needed (5-10 units typical)
- Discuss maintenance schedule (every 3-4 months)

Compliance: the medico-legal angle

• Botulinum Toxin and Cosmetic Fillers (Children) Act 2021 — administering botulinum toxin to anyone under 18 in England is a criminal offence, unless the registered medical practitioner exception applies. The age check is mandatory before any administration.
• GDC Scope of Practice — BTX not listed as dentistry but dentists may prescribe as registered prescribers (with training).
• Human Medicines Regulations 2012 (SI 2012/1916) — botulinum toxin is a POM (prescription-only medicine); record the batch for traceability.
• GDC Guidance on prescribing medicines — "Dentists must not remote prescribe (for example, via telephone, email, or a website) for non-surgical cosmetic procedures, such as the prescription or administration of Botox".
• JCCP (Joint Council for Cosmetic Practitioners) — guidance for cosmetic procedures including BTX.
• Montgomery — extensive consent for elective cosmetic / therapeutic procedure.
• Indemnity — confirm with your provider (DDU, Dental Protection, MDDUS or other) that your BTX work, therapeutic and cosmetic, is covered.

Common documentation mistakes

• No age check recorded — administering BTX to a patient under 18 is a criminal offence under the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021 unless a registered medical practitioner directs it.
• Remote-only / online prescribing for cosmetic BTX — prohibited by GDC Guidance on prescribing medicines.
• No batch / lot number — no traceability for adverse events.
• Injection sites and doses not mapped — indefensible if asymmetry or over-treatment claim.
• No cooling-off period for cosmetic — JCCP best practice ignored.
• No pre-treatment photographs — outcomes disputes have no baseline.

Sources

• GDC: Scope of Practice guidance (revised guidance in effect from 1 November 2025) (accessed 18 October 2026)
• GDC: Guidance on prescribing medicines (accessed 18 October 2026)
• Montgomery v Lanarkshire Health Board (UK Supreme Court, 2015, UKSC 11) (accessed 18 October 2026)
• The Human Medicines Regulations 2012 (SI 2012/1916) (accessed 18 October 2026)
• Botulinum Toxin and Cosmetic Fillers (Children) Act 2021 (accessed 18 October 2026)

Frequently asked questions

Related dental note templates

Browse the full set of free dental notes templates.